Evidence map›Paper›PMID 24164776›Full record

ArticleBreast cancer research : BCR2013

Par-4 prevents breast cancer recurrence.

Nikhil Hebbar, Tripti Shrestha-Bhattarai, Vivek M Rangnekar

Open access · goldAbstract readComment
In one paragraph

Article in Breast cancer research : BCR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Nikhil Hebbar
Tripti Shrestha-Bhattarai
Vivek M Rangnekar
The Graduate Center, CUNY · USUniversity of Kentucky · US

Funding

Mechanism of Apoptosis by Par4R01CA060872 · NCI · UNIVERSITY OF KENTUCKY · PI RANGNEKAR, VIVEK M · 1995 to 2012
$3.3M
NCI NIH HHS CA060872
6 · The paper itself

Abstract

Therapy resistance and disease recurrence are two of the most challenging aspects in breast cancer treatment. A recent article in Cancer Cell makes a significant contribution toward a better understanding of this therapeutic problem by establishing downregulation of the tumor suppressor Par-4 as the primary determinant of breast cancer recurrence. This viewpoint brings forth the importance of their findings and its implications on future research and therapy.

Indexed as

AnimalsApoptosis Regulatory ProteinsBreast NeoplasmsFemaleHumansNeoplasm Recurrence, LocalApoptosis Regulatory Proteins

Identifiers

PMID24164776
PMCPMC3978615
OpenAlexW2109690315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.